News Category
In vitro ADME studies are critical for early evaluation of drug candidates, helping to avoid costly late-stage failures and accelerate the drug develo...
A new study reveals that individual bacterial strains in the microbiome affect the risk of sepsis, meningitis, and pneumonia from air pollution, while...
Peptide Wholesale Supply now provides HPLC chromatographic data for every batch of BPC-157, Semaglutide, and Tirzepatide in bulk orders, enhancing tra...
Experts emphasize that asking about clinical trials at the first appointment can open doors to promising new treatments and improved quality of life f...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial aims to provide independent validation and suppor...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities, offering customized targeted and stimuli-respon...
BioCorRx Inc. has appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Adviso...
Regentis Biomaterials reported a narrowed net loss for the first half of 2026 and progress in its pivotal Phase III trial for GelrinC, a potential fir...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting drug, has received FDA clearance for a Phase 2 trial, potentially offering a new trea...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and a U.S....
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager technolo...
Quantum BioPharma's Lucid-MS has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, potentially offering a novel approach that tar...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective therapy, has received FDA clearance for a Phase 2 trial, potentially transforming the...
Quantum BioPharma's Lucid-MS, the first drug designed to protect and rebuild myelin, receives FDA clearance for a phase 2 trial, potentially transform...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, highlighting the company's late-stage clini...
Onco-Innovations' CMO discusses the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP with a dual selectivity approach, a...
Quantum BioPharma's FDA clearance for its Lucid-MS Investigational New Drug application marks a pivotal step toward a Phase 2 trial, potentially offer...
A new expert analysis reveals that current UTI diagnostic methods often fail to detect underlying causes, leading to recurrent infections and signific...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its progress in developing SPC-15, a nose-to-brain drug delivery sy...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant milestone for a novel myelin-repair approach in multiple sclerosis, d...
Quantum BioPharma's FDA clearance for a Phase 2 trial of its multiple sclerosis drug Lucid-MS has garnered a new buy rating and media spotlight, highl...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to diversify supply and enhance preparedness.
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to bolster its financial leadership and advance its proprietary BiTAC te...
Scinai Immunotherapeutics refocuses its R&D portfolio on its NanoAb platform and CDMO business after terminating its license with PinCell, aiming to p...
Onco-Innovations Ltd. strengthens its clinical foundation through manufacturing milestones, IND-enabling activities, and funding, positioning its PNKP...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial marks a potential breakthrough in treatin...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Ocumetics Technology Corp. has initiated patient recruitment for the second group of its human clinical study, moving beyond safety to evaluate the pe...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a phase 2 trial could herald a new era in MS therapy, add...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Quantum BioPharma gains FDA clearance to begin a Phase 2 trial of Lucid-MS in multiple sclerosis, marking a significant step for a first-in-class ther...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial could revolutionize MS therapy by targeting demyelination rather than immunosuppression, ...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination, could redefine MS therapy by offerin...
Tonix Pharmaceuticals' promotion of Thomas Englese to Chief Commercial Officer underscores the company's strategic focus on commercializing TONMYA, th...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, highlighting the n...
Onco-Innovations has made significant preclinical progress on its PNKP inhibitor ONC010, including high-purity API production and a planned Australian...
OS Therapies' participation in the Moody Capital conference comes as the company anticipates key regulatory decisions and data readouts for its lead c...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, potentia...
The FDA's failure to aggressively enforce laws against the illegal sale of the unapproved drug retatrutide has enabled a dangerous black market, under...
New research reveals that unintended radiation to the thymus during lung cancer treatment is associated with poorer survival, highlighting the need to...
Tonix Pharmaceuticals' participation in the Cantor conference underscores its strategic focus on commercializing TONMYA and advancing its CNS and immu...
NurExone Biologic's participation at the Moody Capital Solutions conference highlights its exosome-based therapies for CNS injuries and its expansion ...
CNS Pharmaceuticals' Chief Business Officer details the company's disciplined approach to building a pipeline in oncology and neurology, emphasizing i...
Dr. Salman Fazal, a hematologist and stem cell transplant expert at UPMC Hillman Cancer Center, has been named a Castle Connolly Top Doctor for 2026, ...
Quantum BioPharma Ltd. has been initiated with a 'Buy' rating and an $8.00 price target by Rodman & Renshaw, highlighting the potential of its lead dr...
NanoViricides is progressing its measles drug candidate NV-387 toward Phase II trials, leveraging FDA designations and promising preclinical data, as ...
TransCode Therapeutics announced preclinical results showing TTX-MC138 improves survival in a breast cancer bone metastasis model, supporting its RNA-...
